PF631 HEALTH-RELATED QUALITY OF LIFE WITH POMALIDOMIDE + LOW-DOSE DEXAMETHASONE + DARATUMUMAB IN PATIENTS WITH RELAPSED REFRACTORY MULTIPLE MYELOMA AFTER LENALIDOMIDE TREATMENT

Autor:	D. Reece, F. Zafar, M. Bar, S. Ganguly, J. Berdeja, B. Anz, Michael Sebag, David S. Siegel, G. Talamo, J. Matous, N.J. Bahlis, K. Song, W. Chung, D. Quick, C. Samaras, G. Fonseca, A. Agarwal, M. Acosta-Rivera, C.S. Seet
Rok vydání:	2019
Předmět:	Oncology Health related quality of life medicine.medical_specialty business.industry Low dose Daratumumab Hematology Pomalidomide medicine.disease Internal medicine Relapsed refractory medicine business Multiple myeloma Dexamethasone medicine.drug Lenalidomide
Zdroj:	HemaSphere. 3:268-269
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000560808.16752.64
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::4dbe3980778b373f0ab0d33bf1284a7b https://doi.org/10.1097/01.hs9.0000560808.16752.64 Zobrazit plný text záznamu Plný text